Focus: Compass Therapeutics is a publicly traded Boston-based biotech focused on antibody therapies and psychedelic-assisted treatments across oncology and neurology indications. The company is in early-stage clinical development with a diversified pipeline but minimal commercial revenue.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
2 added, 1 removed. Backfill posture.
Compass offers meaningful science exposure in emerging therapeutic modalities but carries material execution risk and hiring constraints; suitable only for risk-tolerant candidates committed to early-stage biotech with multi-year value creation horizons.
Help build intelligence for Compass Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Compass Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
If You Invested $1,000 in Compass Therapeutics Inc (CMPX) - Stock Titan
If You Invested $1,000 in Compass Therapeutics Inc (CMPX) Stock Titan
Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success - Stock Titan
Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success Stock Titan
Price to sales forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Price to sales forward of Compass Therapeutics, Inc. – NASDAQ:CMPX TradingView
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000 Growth Benchmark marketscreener.com
CMPX Forecast — Price Target — Prediction for 2027 - TradingView
CMPX Forecast — Price Target — Prediction for 2027 TradingView
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo